News & Events
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
Crinetics announces that the late-breaking abstracts accepted for presentation at ENDO 2024 were released earlier than the previously announced embargoed...
READ MORECrinetics Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its common stock to fifteen new...
READ MORECrinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported first quarter 2024 financial and provided a business update on clinical progress.
READ MORECrinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
Crinetics Pharmaceuticals announced five abstracts from its clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine...
READ MORECrinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Event Date: Crinetics Pharmaceuticals announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets.
READ MORECrinetics Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new...
READ MORETopline Results from Paltusotine Phase 3 PATHFNDR-2 Study
Event Date: March 19, 2024
READ MORECrinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
Crinetics Pharmaceuticals reports positive topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety...
READ MORECrinetics Presents Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome
Event Date: March 12, 2024
READ MORECrinetics Announces Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Crinetics announces positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.